FOLD Q2 2025 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$155M+22.1% YoY

Gross Profit

$139M90.2% margin

Operating Income

-$9M-6.1% margin

Net Income

-$24M-15.8% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+23.5%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$29M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$815M

Total Liabilities

$611M

Stockholders' Equity

$204M

Cash & Equivalents

$159M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$155M	$127M	+22.1%
Gross Profit	$139M	$115M	+20.9%
Operating Income	-$9M	$15M	-163.3%
Net Income	-$24M	-$16M	-55.6%

Geographic Segments

Non-US

$75M58%

UNITED STATES

$54M42%